BioQ Pharma Incorporated and Cipla Limited announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India. BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care. In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,517 INR | +0.34% |
|
+2.03% | +21.74% |
07-15 | Cipla's Manufacturing Unit in Kurkumbh, India Gets VAI Classification from US FDA | MT |
07-05 | Cipla's Philippine-Based Step-Down Subsidiary Gets Dissolved | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.74% | 14.62B | |
+25.94% | 45.32B | |
+34.77% | 24.51B | |
+26.79% | 16.85B | |
+72.37% | 14.16B | |
-0.05% | 6.79B | |
-11.57% | 6.73B | |
+18.15% | 5.82B | |
-8.87% | 5.73B | |
+10.74% | 4.93B |
- Stock Market
- Equities
- CIPLA Stock
- News Cipla Limited
- BioQ Pharma Incorporated and Cipla Limited Announce Strategic Distribution, Supply and Development Agreement